Breast density in NF1 women: a retrospective study.
Breast cancer
Breast density
Neurofibromatosis type 1
Screening
Journal
Familial cancer
ISSN: 1573-7292
Titre abrégé: Fam Cancer
Pays: Netherlands
ID NLM: 100898211
Informations de publication
Date de publication:
25 Jan 2024
25 Jan 2024
Historique:
received:
18
10
2023
accepted:
18
12
2023
medline:
25
1
2024
pubmed:
25
1
2024
entrez:
25
1
2024
Statut:
aheadofprint
Résumé
Neurofibromatosis type 1 (NF1) is an autosomal dominant condition caused by neurofibromin haploinsufficiency due to pathogenic variants in the NF1 gene. Tumor predisposition has long been associated with NF1, and an increased breast cancer (BC) incidence and reduced survival have been reported in recent years for women with NF1. As breast density is another known independent risk factor for BC, this study aims to evaluate the variability of breast density in patients with NF1 compared to the general population. Mammograms from 98 NF1 women affected by NF1, and enrolled onto our monocentric BC screening program, were compared with those from 300 healthy subjects to verify differences in breast density. Mammograms were independently reviewed and scored by a radiologist and using a Computer-Aided Detection (CAD) software. The comparison of breast density between NF1 patients and controls was performed through Chi-squared test and with multivariable ordinal logistic models adjusted for age, body mass index (BMI), number of pregnancies, and menopausal status.breast density was influenced by BMI and menopausal status in both NF1 patients and healthy subjects. No difference in breast density was observed between NF1 patients and the healthy female population, even after considering the potential confounding factors.Although NF1 and a highly fibroglandular breast are known risk factors of BC, in this study, NF1 patients were shown to have comparable breast density to healthy subjects. The presence of pathogenic variants in the NF1 gene does not influence the breast density value.
Identifiants
pubmed: 38270845
doi: 10.1007/s10689-023-00355-y
pii: 10.1007/s10689-023-00355-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Uusitalo E, Leppävirta J, Koffert A, Suominen S, Vahtera J, Vahlberg T et al (2015) Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol 135:904–906. https://doi.org/10.1038/jid.2014.465
doi: 10.1038/jid.2014.465
pubmed: 25354145
Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM et al (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A:327–332. https://doi.org/10.1002/ajmg.a.33139
doi: 10.1002/ajmg.a.33139
pubmed: 20082463
Gutmann DH, Collins FS (1993) The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron 10:335–343. https://doi.org/10.1016/0896-6273(93)90324-k
doi: 10.1016/0896-6273(93)90324-k
pubmed: 8461130
Anastasaki C, Orozco P, Gutmann DH (2022) RAS and beyond: the many faces of the neurofibromatosis type 1 protein. Dis Models Mech 15:dmm049362. https://doi.org/10.1242/dmm.049362
doi: 10.1242/dmm.049362
Friedman JM (1993) In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, Gripp KW, GeneReviews® et al (eds) Neurofibromatosis 1. University of Washington, Seattle, Seattle (WA)
Madanikia SA, Bergner A, Ye X, Blakeley JO (2012) Increased risk of Breast Cancer in women with NF1. Am J Med Genet A 158A:3056–3060. https://doi.org/10.1002/ajmg.a.35550
doi: 10.1002/ajmg.a.35550
pubmed: 23165953
pmcid: 3507419
Sharif S, Moran A, Huson SM, Iddenden R, Shenton A, Howard E et al (2007) Women with neurofibromatosis 1 are at a moderately increased risk of developing Breast cancer and should be considered for early screening. J Med Genet 44:481–484. https://doi.org/10.1136/jmg.2007.049346
doi: 10.1136/jmg.2007.049346
pubmed: 17369502
pmcid: 2597938
Howell SJ, Hockenhull K, Salih Z, Evans DG (2017) Increased risk of Breast cancer in neurofibromatosis type 1: current insights. Breast Cancer (Dove Med Press 9:531–536. https://doi.org/10.2147/BCTT.S111397
doi: 10.2147/BCTT.S111397
pubmed: 28860858
Walker L, Thompson D, Easton D, Ponder B, Ponder M, Frayling I et al (2006) A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 95:233–238. https://doi.org/10.1038/sj.bjc.6603227
doi: 10.1038/sj.bjc.6603227
pubmed: 16786042
pmcid: 2360616
Uusitalo E, Rantanen M, Kallionpää RA, Pöyhönen M, Leppävirta J, Ylä-Outinen H et al (2016) Distinctive Cancer associations in patients with neurofibromatosis type 1. J Clin Oncol 34:1978–1986. https://doi.org/10.1200/JCO.2015.65.3576
doi: 10.1200/JCO.2015.65.3576
pubmed: 26926675
Evans DG (2012) Are we ready for targeted early Breast cancer detection strategies in women with NF1 aged 30–49 years? Am J Med Genet A 158A:3054–3055. https://doi.org/10.1002/ajmg.a.35585
doi: 10.1002/ajmg.a.35585
pubmed: 22987630
Suarez-Kelly LP, Yu L, Kline D, Schneider EB, Agnese DM, Carson WE (2019) Increased Breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature. Hered Cancer Clin Pract 17:12. https://doi.org/10.1186/s13053-019-0110-z
doi: 10.1186/s13053-019-0110-z
pubmed: 30962859
pmcid: 6434896
Philpott C, Tovell H, Frayling IM, Cooper DN, Upadhyaya M (2017) The NF1 somatic mutational landscape in sporadic human cancers. Hum Genomics 11:13. https://doi.org/10.1186/s40246-017-0109-3
doi: 10.1186/s40246-017-0109-3
pubmed: 28637487
pmcid: 5480124
Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B et al (2016) Genetic/Familial High-Risk Assessment: breast and ovarian, Version 2.2015. J Natl Compr Canc Netw 14:153–162. https://doi.org/10.6004/jnccn.2016.0018
doi: 10.6004/jnccn.2016.0018
pubmed: 26850485
Carton C, Evans DG, Blanco I, Friedrich RE, Ferner RE, Farschtschi S et al (2023) ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine 56:101818. https://doi.org/10.1016/j.eclinm.2022.101818
doi: 10.1016/j.eclinm.2022.101818
pubmed: 36684394
pmcid: 9845795
Tsarouchi MI, Hoxhaj A, Mann RM (2023) New approaches and recommendations for risk-adapted Breast Cancer screening. J Magn Reson Imaging 58:987–1010. https://doi.org/10.1002/jmri.28731
doi: 10.1002/jmri.28731
pubmed: 37040474
Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E et al (2007) Mammographic density and the risk and detection of Breast cancer. N Engl J Med 356:227–236. https://doi.org/10.1056/NEJMoa062790
doi: 10.1056/NEJMoa062790
pubmed: 17229950
Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH (2003) Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 5:R129–135. https://doi.org/10.1186/bcr622
doi: 10.1186/bcr622
pubmed: 12927043
pmcid: 314426
Evans DG, van Veen EM, Howell A, Astley S (2020) Heritability of mammographic breast density. Quant Imaging Med Surg 10:2387391–2382391. https://doi.org/10.21037/qims-2020-20
doi: 10.21037/qims-2020-20
Sung J, Song Y-M, Stone J, Lee K, Jeong J-I, Kim S-S (2010) Genetic influences on mammographic density in Korean twin and family: the healthy twin study. Breast Cancer Res Treat 124:467–474. https://doi.org/10.1007/s10549-010-0852-9
doi: 10.1007/s10549-010-0852-9
pubmed: 20349128
Mann RM, Athanasiou A, Baltzer PAT, Camps-Herrero J, Clauser P, Fallenberg EM et al (2022) Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI). Eur Radiol 32:4036–4045. https://doi.org/10.1007/s00330-022-08617-6
doi: 10.1007/s00330-022-08617-6
pubmed: 35258677
pmcid: 9122856
Brosseau J-P, Sathe AA, Wang Y, Nguyen T, Glass DA, Xing C et al (2021) Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing. Acta Neuropathol Commun 9:11. https://doi.org/10.1186/s40478-020-01103-4
doi: 10.1186/s40478-020-01103-4
pubmed: 33413690
pmcid: 7792184
http:// malattierare.marionegri.it/images/downloads/PDTA/PDTA_schede/nf1.pdf
Shang MY, Guo S, Cui MK, Zheng YF, Liao ZX, Zhang Q et al (2021) Influential factors and prediction model of mammographic density among Chinese women. Med (Baltim) 100:e26586. https://doi.org/10.1097/MD.0000000000026586
doi: 10.1097/MD.0000000000026586
Breast Imaging Reporting & (2023) Data System n.d. https://www.acr.org/Clinical-Resources/Reporting-and-Data Systems/Bi-Rads
Brem RF, Hoffmeister JW, Rapelyea JA, Zisman G, Mohtashemi K, Jindal G et al (2005) Impact of breast density on computer-aided detection for Breast cancer. AJR Am J Roentgenol 184:439–444. https://doi.org/10.2214/ajr.184.2.01840439
doi: 10.2214/ajr.184.2.01840439
pubmed: 15671360
Statistical software for (2023) data science | Stata n.d. https://www.stata.com/
Rasmussen SA, Yang Q, Friedman JM (2001) Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 68:1110–1118. https://doi.org/10.1086/320121
doi: 10.1086/320121
pubmed: 11283797
pmcid: 1226092
McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of Breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:1159–1169. https://doi.org/10.1158/1055-9965.EPI-06-0034
doi: 10.1158/1055-9965.EPI-06-0034
pubmed: 16775176
Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR et al (2003) Mammographic density and Breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 12:332–338
pubmed: 12692108
Passaperuma K, Warner E, Hill KA, Gunasekara A, Yaffe MJ (2010) Is mammographic breast density a Breast cancer risk factor in women with BRCA mutations? J Clin Oncol 28:3779–3783. https://doi.org/10.1200/JCO.2009.27.5933
doi: 10.1200/JCO.2009.27.5933
pubmed: 20625126
Han Y, Moore JX, Colditz GA, Toriola AT (2022) Family history of Breast Cancer and mammographic breast density in Premenopausal Women. JAMA Netw Open 5:e2148983. https://doi.org/10.1001/jamanetworkopen.2021.48983
doi: 10.1001/jamanetworkopen.2021.48983
pubmed: 35175341
pmcid: 8855232
Ziv E, Shepherd J, Smith-Bindman R, Kerlikowske K (2003) Mammographic breast density and family history of Breast cancer. J Natl Cancer Inst 95:556–558. https://doi.org/10.1093/jnci/95.7.556
doi: 10.1093/jnci/95.7.556
pubmed: 12671024
Lindström S, Thompson DJ, Paterson AD, Li J, Gierach GL, Scott C et al (2014) Genome-wide association study identifies multiple loci associated with both mammographic density and Breast cancer risk. Nat Commun 5:5303. https://doi.org/10.1038/ncomms6303
doi: 10.1038/ncomms6303
pubmed: 25342443
Gokalp G, Hakyemez B, Kizilkaya E, Haholu A (2007) Myxoid neurofibromas of the breast: mammographical, sonographical and MRI appearances. Br J Radiol 80:e234–237. https://doi.org/10.1259/bjr/33539044
doi: 10.1259/bjr/33539044
pubmed: 17959912
Maani N, Westergard S, Yang J, Scaranelo AM, Telesca S, Thain E et al (2019) NF1 patients receiving Breast Cancer screening: insights from the Ontario High Risk breast screening program. Cancers (Basel) 11:707. https://doi.org/10.3390/cancers11050707 Web references
doi: 10.3390/cancers11050707
pubmed: 31121919